investorscraft@gmail.com

Intrinsic value of CollPlant Holdings Ltd. Sponsored ADR (CLGN)

Previous Close$4.71
Intrinsic Value
Upside potential
Previous Close
$4.71

VALUATION INPUT DATA (original, your and others' valuations)

ParameterOrig.Your
Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh3.44 

The original valuation is based on fiscal year data as of 2021-12-31 and quarterly data as of 2021-12-31.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bio-printing of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company's products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. Its products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants; VergenixSTR, a soft tissue repair matrix intended for treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2021(a)2022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046

INCOME STATEMENT

Revenue growth rate, %154.9NaN
Revenue, $16NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m16NaN
Operating income, $m0NaN
EBITDA, $m1NaN
Interest expense (income), $mNaN
Earnings before tax, $m6NaN
Tax expense, $m5NaN
Net income, $m0NaN

BALANCE SHEET

Cash and short-term investments, $m43NaN
Total assets, $m51NaN
Adjusted assets (=assets-cash), $m8NaN
Average production assets, $m5NaN
Working capital, $m42NaN
Total debt, $m4NaN
Total liabilities, $m6NaN
Total equity, $m45NaN
Debt-to-equity ratio0.080NaN
Adjusted equity ratio0.294NaN

CASH FLOW

Net income, $m0NaN
Depreciation, amort., depletion, $m1NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m3NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-1NaN
Free cash flow, $m4NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m42
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount